These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11532074)

  • 1. Development of potent glucagon antagonists: structure-activity relationship study of glycine at position 4.
    Ahn JM; Medeiros M; Trivedi D; Hruby VJ
    J Pept Res; 2001 Aug; 58(2):151-8. PubMed ID: 11532074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic peptide antagonists of glucagon.
    Unson CG; Andreu D; Gurzenda EM; Merrifield RB
    Proc Natl Acad Sci U S A; 1987 Jun; 84(12):4083-7. PubMed ID: 3035568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon antagonists: contribution to binding and activity of the amino-terminal sequence 1-5, position 12, and the putative alpha-helical segment 19-27.
    Unson CG; Gurzenda EM; Iwasa K; Merrifield RB
    J Biol Chem; 1989 Jan; 264(2):789-94. PubMed ID: 2536024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon antagonists. Synthesis and inhibitory properties of Asp3-containing glucagon analogs.
    Andreu D; Merrifield RB
    Eur J Biochem; 1987 May; 164(3):585-90. PubMed ID: 3032623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of an essential serine residue in glucagon: implication for an active site triad.
    Unson CG; Merrifield RB
    Proc Natl Acad Sci U S A; 1994 Jan; 91(2):454-8. PubMed ID: 8290548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of 2-thioltryptophan-glucagon and (tryptophan-S-glucagon)2. Differences in binding to the glucagon receptor in the hepatic adenylate cyclase system.
    Wright DE; Rodbell M
    J Biol Chem; 1980 Nov; 255(22):10884-7. PubMed ID: 7430160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semisynthetic D-His1,N epsilon-acetimidoglucagon: structure-function relationships.
    Mahrenholz AM; Flanders KC; Hoosein NM; Gurd FR; Gurd RS
    Arch Biochem Biophys; 1987 Sep; 257(2):379-86. PubMed ID: 2821912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor binding and adenylate cyclase activities of glucagon analogues modified in the N-terminal region.
    McKee RL; Pelton JT; Trivedi D; Johnson DG; Coy DH; Sueiras-Diaz J; Hruby VJ
    Biochemistry; 1986 Apr; 25(7):1650-6. PubMed ID: 3011069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new approach to search for the bioactive conformation of glucagon: positional cyclization scanning.
    Ahn JM; Gitu PM; Medeiros M; Swift JR; Trivedi D; Hruby VJ
    J Med Chem; 2001 Sep; 44(19):3109-16. PubMed ID: 11543679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of specific trinitrophenylation of the lysine epsilon amino group of glucagon on receptor binding and adenylate cyclase activation.
    Liepnieks JJ; Epand RM
    Arch Biochem Biophys; 1983 Aug; 225(1):102-9. PubMed ID: 6311099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor occupancy and adenylate cyclase activation in rat liver and heart membranes by 10 glucagon analogs modified in position 2,3, 4, 25, 27 and/or 29.
    Robberect P; Damien C; Moroder L; Coy DH; Wünsch E; Christophe J
    Regul Pept; 1988 May; 21(1-2):117-28. PubMed ID: 2839870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topographical amino acid substitution in position 10 of glucagon leads to antagonists/partial agonists with greater binding differences.
    Azizeh BY; Shenderovich MD; Trivedi D; Li G; Sturm NS; Hruby VJ
    J Med Chem; 1996 Jun; 39(13):2449-55. PubMed ID: 8691441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic linear and cyclic glucagon antagonists.
    Dharanipragada R; Trivedi D; Bannister A; Siegel M; Tourwe D; Mollova N; Schram K; Hruby VJ
    Int J Pept Protein Res; 1993 Jul; 42(1):68-77. PubMed ID: 8396562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of potent truncated glucagon antagonists.
    Ahn JM; Medeiros M; Trivedi D; Hruby VJ
    J Med Chem; 2001 Apr; 44(9):1372-9. PubMed ID: 11311060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-conformation-activity studies of glucagon and semi-synthetic glucagon analogs.
    Hruby VJ
    Mol Cell Biochem; 1982 Apr; 44(1):49-64. PubMed ID: 6283336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological activities of des-His1[Glu9]glucagon amide, a glucagon antagonist.
    Unson CG; Gurzenda EM; Merrifield RB
    Peptides; 1989; 10(6):1171-7. PubMed ID: 2560175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of phenylalanine at position 6 in glucagon's mechanism of biological action: multiple replacement analogues of glucagon.
    Azizeh BY; Ahn JM; Caspari R; Shenderovich MD; Trivedi D; Hruby VJ
    J Med Chem; 1997 Aug; 40(16):2555-62. PubMed ID: 9258362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity studies of hydrophobic amino acid replacements at positions 9, 11 and 16 of glucagon.
    Sturm NS; Hutzler AM; David CS; Azizeh BY; Trivedi D; Hruby VJ
    J Pept Res; 1997 Apr; 49(4):293-9. PubMed ID: 9176812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of histidine-1 in glucagon action.
    Unson CG; Macdonald D; Merrifield RB
    Arch Biochem Biophys; 1993 Feb; 300(2):747-50. PubMed ID: 8382034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation and properties of glucagon analogs prepared by semi-synthesis from CNBr-glucagon.
    Wright DE; Hruby VJ; Rodbell M
    Biochim Biophys Acta; 1980 Aug; 631(1):49-58. PubMed ID: 6249392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.